

Alasdair J Coles

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9449649/alsadair-j-coles-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105
papers

13,643
citations

42
h-index

112
g-index

112
ext. papers

15,616
ext. citations

9.1
avg, IF

6.66
L-index

#	Paper	IF	Citations
105	Campath, clones and the cause of autoimmunity. <i>Brain</i> , 2022 , 145, 1579-1580	11.2	
104	Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 57, 103458	4	10
103	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 295-302	5.5	5
102	Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
101	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. <i>Journal of Immunology</i> , 2021 ,	5.3	6
100	Promoting remyelination in multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 30-44	5.5	34
99	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286420982134	6.6	11
98	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 52, 102939	4	12
97	Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution. <i>Journal of Neurology</i> , 2021 , 1	5.5	0
96	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. <i>Lancet Neurology, The</i> , 2021 , 20, 709-720	24.1	6
95	Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. <i>Lancet, The</i> , 2021 , 398, 1147-1156	40	51
94	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061335	5.5	11061335
93	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
92	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 875-891	5.3	28
91	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology, The</i> , 2020 , 19, 307-316	24.1	77
90	Hyperpolarized C MRI: A novel approach for probing cerebral metabolism in health and neurological disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020 , 40, 1137-1147	7.3	24
89	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. <i>Contemporary Clinical Trials</i> , 2020 , 95, 106009	2.3	9

88	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
87	Guidelines on the use of irradiated blood components. <i>British Journal of Haematology</i> , 2020 , 191, 704-724	4.5	25
86	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1093-1101	5	5
85	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 ,	5.5	25
84	Quantifying normal human brain metabolism using hyperpolarized [1-C]pyruvate and magnetic resonance imaging. <i>NeuroImage</i> , 2019 , 189, 171-179	7.9	92
83	Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2). <i>Trials</i> , 2019 , 20, 331	2.8	6
82	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1273-1288	5	23
81	Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 365-367	5.5	16
80	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. <i>JCI Insight</i> , 2019 , 5,	9.9	10
79	A case of anaphylaxis to alemtuzumab. <i>Journal of Neurology</i> , 2019 , 266, 780-781	5.5	1
78	Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 304-315	3.8	23
77	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
76	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1605-1617	5	46
75	Alemtuzumab as Treatment for Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018 , 8,	5.4	9
74	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. <i>Brain</i> , 2018 , 141, 786-796	16.2	23
73	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. <i>Neurology</i> , 2018 , 90, 849-851	6.5	25
72	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3010-3018	5.6	35
71	Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. <i>BMJ Open</i> , 2018 , 8, e025333	3	37

70	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1779-1782	5	21
69	Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. <i>Neurology</i> , 2017 , 88, 1004-1006	6.5	27
68	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281	24.1	101
67	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , 2017 , 89, 1107-1116	6.5	139
66	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , 2017 , 89, 1117-1126	6.5	175
65	Physician-assisted death should be available to people with MS - Commentary. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1681	5	5
64	Hypothyroid ataxia complicating monoclonal antibody therapy. <i>Practical Neurology</i> , 2017 , 17, 482-484	2.4	3
63	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. <i>JCI Insight</i> , 2017 , 2,	9.9	26
62	A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers. <i>Journal of Neuroimmunology</i> , 2017 , 312, 4-7	3.5	1
61	Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology. <i>Rheumatology</i> , 2017 , 56, 668-670	3.9	0
60	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β1a in MS. <i>Neurology</i> , 2016 , 87, 1464-1472	6.5	21
59	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. <i>Journal of Neurology</i> , 2016 , 263, 25-9	5.5	33
58	Alemtuzumab improves neurological functional systems in treatment-naïve relapsing-remitting multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 188-94	3.2	9
57	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016 , 87, 1985-1992	6.5	38
56	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. <i>Practical Neurology</i> , 2015 , 15, 273-9	2.4	118
55	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 208-15	5.5	164
54	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 708-13	5.5	81
53	Newer therapies for multiple sclerosis. <i>Annals of Indian Academy of Neurology</i> , 2015 , 18, S30-4	0.9	9

52	Mode of action and clinical studies with alemtuzumab. <i>Experimental Neurology</i> , 2014 , 262 Pt A, 37-43	5.7	43
51	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. <i>Neurology</i> , 2014 , 82, 2158-64	6.5	44
50	Product licences for alemtuzumab and multiple sclerosis. <i>Lancet, The</i> , 2014 , 383, 867-8	4.0	6
49	Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 237-43	4	17
48	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 795-8	5.5	34
47	Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series. <i>Schizophrenia Research</i> , 2014 , 160, 193-5	3.6	53
46	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 66-8	3.5	24
45	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. <i>Journal of Neurology</i> , 2013 , 260, 462-9	5.5	22
44	The outlook for alemtuzumab in multiple sclerosis. <i>BioDrugs</i> , 2013 , 27, 181-9	7.9	6
43	Immune competence after alemtuzumab treatment of multiple sclerosis. <i>Neurology</i> , 2013 , 81, 872-6	6.5	95
42	Alemtuzumab therapy for multiple sclerosis. <i>Neurotherapeutics</i> , 2013 , 10, 29-33	6.4	58
41	Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013 , 2, 60-3	4	26
40	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. <i>Brain</i> , 2013 , 136, 2888-903	11.2	130
39	Alemtuzumab treatment of multiple sclerosis. <i>Seminars in Neurology</i> , 2013 , 33, 66-73	3.2	24
38	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 20200-5	11.5	149
37	Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. <i>Therapeutic Advances in Chronic Disease</i> , 2013 , 4, 97-103	4.9	11
36	Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 241-4	5	32
35	Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. <i>Drug Design, Development and Therapy</i> , 2013 , 7, 131-8	4.4	25

34 Targeting CD52 for the Treatment of Multiple Sclerosis **2013**, 385-399

33	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1819-28	4.0	834
32	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39	4.0	827
31	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 298-304	5.5	148
30	We are about to cure MS in the next 10 years, even though we do not know its cause: no. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 784-5	5	
29	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. <i>Blood</i> , 2011 , 118, 6299-305	2.2	84
28	Alemtuzumab versus interferon β 1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. <i>Lancet Neurology, The</i> , 2011 , 10, 338-48	24.1	108
27	Disease-relevant autoantibodies in first episode schizophrenia. <i>Journal of Neurology</i> , 2011 , 258, 686-8	5.5	236
26	Radiologically compatible CLIPPERS may conceal a number of pathologies. <i>Brain</i> , 2011 , 134, e187	11.2	22
25	Alemtuzumab in Multiple Sclerosis. <i>Noropsikiyatri Arsivi</i> , 2011 , 48, 79-82	0.4	1
24	Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. <i>Journal of Clinical Investigation</i> , 2010 , 120, 4220-35	15.9	229
23	A novel strategy to reduce the immunogenicity of biological therapies. <i>Journal of Immunology</i> , 2010 , 185, 763-8	5.3	58
22	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. <i>Brain</i> , 2010 , 133, 2232-47	11.2	131
21	New treatment strategies in multiple sclerosis. <i>Experimental Neurology</i> , 2010 , 225, 34-9	5.7	31
20	Alemtuzumab for the treatment of multiple sclerosis. <i>Future Neurology</i> , 2010 , 5, 177-188	1.5	
19	B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. <i>Journal of Clinical Immunology</i> , 2010 , 30, 99-105	5.7	180
18	Monoclonal antibodies in multiple sclerosis treatment: current and future steps. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 195-203	6.6	15
17	Multiple sclerosis. <i>Practical Neurology</i> , 2009 , 9, 118-26	2.4	15

16	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). <i>Journal of Clinical Investigation</i> , 2009 , 119, 2052-61	15.9	215
15	Multiple sclerosis. <i>Lancet, The</i> , 2008 , 372, 1502-17	40	3360
14	Campath-1H treatment of multiple sclerosis. <i>Neurodegenerative Diseases</i> , 2008 , 5, 27-31	2.3	30
13	Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. <i>New England Journal of Medicine</i> , 2008 , 359, 1786-801	59.2	769
12	The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. <i>Journal of Neurology</i> , 2006 , 253, 98-108	5.5	401
11	Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. <i>European Journal of Immunology</i> , 2005 , 35, 3694-703	6.1	42
10	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. <i>European Journal of Immunology</i> , 2005 , 35, 3332-42	6.1	248
9	Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. <i>Clinical Neurology and Neurosurgery</i> , 2004 , 106, 270-4	2	76
8	Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. <i>European Journal of Neuroscience</i> , 2003 , 18, 2527-37	3.5	64
7	Multiple sclerosis. <i>Lancet, The</i> , 2002 , 359, 1221-31	40	1618
6	Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. <i>Annals of Neurology</i> , 1999 , 46, 296-304	9.4	438
5	Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. <i>Lancet, The</i> , 1999 , 354, 1691-5	40	398
4	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. <i>Brain</i> , 1996 , 119 (Pt 1), 225-37	11.2	227
3	Alemtuzumab to treat multiple sclerosis 393-398		
2	Recent thymic emigrants produce antimicrobial IL-8, express complement receptors and are precursors of a tissue-homing Th8 lineage of memory cells		1
1	COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies		1